Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Quintero

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Chemosphere|April 24, 2007
Determination of selenium by GFAAS in slurries of fish feces to estimate the bioavailability of this micronutrient in feed used in piscicultureFábio A Silva, Renato C F Neves, Luis G Quintero-Pinto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 8, 2019
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trialG Quintero Aldana, M Salgado, S Candamio, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2018
Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)Jeffrey J Letourneau, Ilana L Stroke, David W Hilbert, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2015
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancerG Quintero-Aldana, M Jorge, C Grande, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2018
Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)Jeffrey J Letourneau, Ilana L Stroke, David W Hilbert, et al.
Immunopharmacology|December 22, 1999
Small molecule antagonists of the bradykinin B1 receptorR A Horlick, M H Ohlmeyer, I L Stroke, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2023
Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506Andrew G Cole, Steven G Kultgen, Nagraj Mani, et al.
Clinical Colorectal Cancer|March 21, 2023
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized TrialsP Jiménez-Fonseca, J Sastre, P García-Alfonso, et al.
ESMO Open|November 28, 2024
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trialP García-Alfonso, E Elez, J Soto-Alsar, et al.
ESMO Open|March 12, 2021
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 studyJ Sastre, P García-Alfonso, J M Viéitez, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Chemosphere|April 24, 2007
Determination of selenium by GFAAS in slurries of fish feces to estimate the bioavailability of this micronutrient in feed used in piscicultureFábio A Silva, Renato C F Neves, Luis G Quintero-Pinto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 8, 2019
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trialG Quintero Aldana, M Salgado, S Candamio, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2018
Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)Jeffrey J Letourneau, Ilana L Stroke, David W Hilbert, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2015
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancerG Quintero-Aldana, M Jorge, C Grande, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2018
Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB)Jeffrey J Letourneau, Ilana L Stroke, David W Hilbert, et al.
Immunopharmacology|December 22, 1999
Small molecule antagonists of the bradykinin B1 receptorR A Horlick, M H Ohlmeyer, I L Stroke, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2023
Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506Andrew G Cole, Steven G Kultgen, Nagraj Mani, et al.
Clinical Colorectal Cancer|March 21, 2023
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized TrialsP Jiménez-Fonseca, J Sastre, P García-Alfonso, et al.
ESMO Open|November 28, 2024
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trialP García-Alfonso, E Elez, J Soto-Alsar, et al.
ESMO Open|March 12, 2021
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 studyJ Sastre, P García-Alfonso, J M Viéitez, et al.
Pageof 6